JPS637779A - Cell activator - Google Patents
Cell activatorInfo
- Publication number
- JPS637779A JPS637779A JP15094786A JP15094786A JPS637779A JP S637779 A JPS637779 A JP S637779A JP 15094786 A JP15094786 A JP 15094786A JP 15094786 A JP15094786 A JP 15094786A JP S637779 A JPS637779 A JP S637779A
- Authority
- JP
- Japan
- Prior art keywords
- group
- silicon compound
- cell
- methyltrisilanol
- cell activator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012190 activator Substances 0.000 title claims abstract description 13
- 150000003377 silicon compounds Chemical class 0.000 claims abstract description 15
- SHEYKHMHFCPWCL-UHFFFAOYSA-N disilanyl-hydroxy-methylsilane Chemical compound C[SiH](O)[SiH2][SiH3] SHEYKHMHFCPWCL-UHFFFAOYSA-N 0.000 claims abstract description 14
- 125000005372 silanol group Chemical group 0.000 claims abstract description 6
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 3
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 abstract description 5
- 239000002904 solvent Substances 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 230000018044 dehydration Effects 0.000 abstract 1
- 238000006297 dehydration reaction Methods 0.000 abstract 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- -1 octyltrisilanol Chemical compound 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000001339 epidermal cell Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003729 cation exchange resin Substances 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- KKTUQAYCCLMNOA-UHFFFAOYSA-N 2,3-diaminobenzoic acid Chemical compound NC1=CC=CC(C(O)=O)=C1N KKTUQAYCCLMNOA-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- FXHMPXXENORCTG-UHFFFAOYSA-N CCO[SiH](O)[SiH2][SiH3] Chemical compound CCO[SiH](O)[SiH2][SiH3] FXHMPXXENORCTG-UHFFFAOYSA-N 0.000 description 1
- VSTDKEWSKBIOMX-UHFFFAOYSA-N CC[SiH](O)[SiH2][SiH3] Chemical compound CC[SiH](O)[SiH2][SiH3] VSTDKEWSKBIOMX-UHFFFAOYSA-N 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010048218 Xeroderma Diseases 0.000 description 1
- PUWRRFJWMBAYMQ-UHFFFAOYSA-L [Na+].[Na+].[Na+].CP([O-])([O-])=O Chemical compound [Na+].[Na+].[Na+].CP([O-])([O-])=O PUWRRFJWMBAYMQ-UHFFFAOYSA-L 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- VVOOXZLSKZCCJW-UHFFFAOYSA-N benzyl-(disilanyl)-hydroxysilane Chemical compound O[SiH](Cc1ccccc1)[SiH2][SiH3] VVOOXZLSKZCCJW-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- PMWBHKAFJHMDJA-UHFFFAOYSA-N cyclohexyl-(disilanyl)-hydroxysilane Chemical compound C1(CCCCC1)[SiH]([SiH2][SiH3])O PMWBHKAFJHMDJA-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- CPKTUMHHHOVSQC-UHFFFAOYSA-N diethyl-hydroxy-silylsilane Chemical compound CC[Si](O)([SiH3])CC CPKTUMHHHOVSQC-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- ZOAYMOGNAWSEJE-UHFFFAOYSA-N disilanyl-hydroxy-(2-phenylethyl)silane Chemical compound [SiH3][SiH2][SiH](O)CCC1=CC=CC=C1 ZOAYMOGNAWSEJE-UHFFFAOYSA-N 0.000 description 1
- DEMBLQQOHCYCLE-UHFFFAOYSA-N disilanyl-hydroxy-propylsilane Chemical compound CCC[SiH](O)[SiH2][SiH3] DEMBLQQOHCYCLE-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WXKKFJKVDIJRDT-UHFFFAOYSA-N hydroxy-dimethyl-silylsilane Chemical compound C[Si](C)(O)[SiH3] WXKKFJKVDIJRDT-UHFFFAOYSA-N 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000005055 methyl trichlorosilane Substances 0.000 description 1
- JLUFWMXJHAVVNN-UHFFFAOYSA-N methyltrichlorosilane Chemical compound C[Si](Cl)(Cl)Cl JLUFWMXJHAVVNN-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- SCPYDCQAZCOKTP-UHFFFAOYSA-N silanol Chemical compound [SiH3]O SCPYDCQAZCOKTP-UHFFFAOYSA-N 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- AAPLIUHOKVUFCC-UHFFFAOYSA-N trimethylsilanol Chemical compound C[Si](C)(C)O AAPLIUHOKVUFCC-UHFFFAOYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、細胞を賦活化することによって創傷の治癒を
促進したり、細胞培養系に添加して細胞の増殖を促進さ
せることができる細胞賦活剤に関するものである。[Detailed Description of the Invention] [Industrial Application Field] The present invention provides cells that can be used to promote wound healing by activating cells or to promote cell proliferation by being added to a cell culture system. It concerns an activator.
近年、組織培養技術の急速な進歩により、生体の組織レ
ベルでの種々の変化を細胞レベルで解明することが可能
になってきた。特に細胞培養法の急速な発達により多く
の生命現象が、明らかにされつつある。ところで、細胞
培養法では細胞を生存させ、かつ増殖させるために、ビ
タミン、糖、アミノ酸等を配合した合成培地に、通常、
血清を１０％程度添加することが行なわれている。これ
は、血清が有する細胞増殖作用を利用するものであるが
、血清は品質の振れが大きいといった問題がある。そこ
で、最近では、血清を用いる不便さを解消するために無
血清培地の開発が要望されており、そのための適切な栄
ｖ源、及びホルモン以外の新しい細り包成長因子の開発
が望まれている。In recent years, rapid advances in tissue culture technology have made it possible to elucidate various changes at the tissue level of living organisms at the cellular level. In particular, many biological phenomena are being clarified due to the rapid development of cell culture methods. By the way, in cell culture methods, in order to keep cells alive and proliferate, a synthetic medium containing vitamins, sugars, amino acids, etc. is usually used.
It is common practice to add about 10% serum. This utilizes the cell proliferation effect of serum, but there is a problem in that the quality of serum varies widely. Therefore, recently there has been a demand for the development of a serum-free medium to eliminate the inconvenience of using serum, and for this purpose, it is desired to develop an appropriate nutritional source and a new growth factor other than hormones. .
尚、従来から知られているホルモンやタンパク質などの
細胞増慝因子を用いたのでは、未だ効果が十分ではない
といった問題があった。However, the use of conventionally known cell-promoting factors such as hormones and proteins has been problematic in that the effects are not sufficient.
こ発明が解決しようとする問題点〕
従って、本発明は、品質等の振れが少な゛く、すぐれた
細胞賦活作用を有する細胞賦活剤、すなわち合成の細胞
賦活剤を提供することを目的とする。[Problems to be Solved by the Present Invention] Therefore, an object of the present invention is to provide a cell activator having excellent cell activating effects with less variation in quality, that is, a synthetic cell activator. .
口問題点を解決するための手段〕
本発明は、種々の化合物について幅広い研究を行なった
結果、特定のケイ素化合物が細胞培養系にとどまるず種
々の系において幅広くすぐれた細胞賦活作用を有すると
の知見に基づいてなされたのである。[Means for Solving the Problems] The present invention has been made based on extensive research on various compounds, and has revealed that a specific silicon compound has a wide range of excellent cell activating effects not only in cell culture systems but also in various systems. This was done based on knowledge.
すなわち、本発明は、分子内にシラノール基を少くとも
一個有するケイ素化合物を含有することを特徴とする細
胞賦活剤を提供する。That is, the present invention provides a cell activator characterized by containing a silicon compound having at least one silanol group in the molecule.
本発明で用しするケイ素化合物は、分子中に少なくとも
１つのシラノール基を有するケイ素化合物であればいず
れでもよいが、好ましくは一般式％式％）：
（式中、Ｒは、炭素数１〜１２、好ましくは１〜６のア
ルキル基、アラルキル基、アルケニル基、シクロアルキ
ル基、またはアルコキシ基であり、２以上のＲは互いに
同一でも異なっても良く、ｎは０〜３、好ましくは１〜
３の整数である。）
で表わされる化合物又はこれらの脱水縮合体を用いるの
がよい。これらのケイ素化合物として、具体的には、メ
チルトリシラノール、ジメチルジシラノール、トリメチ
ルシラノール、エチルトリシラノール、ジエチルジシラ
ノール、プロピルトリシラノール、オクチルトリシラノ
ール、ドデシルトリシラノール、ベンジルトリシラノー
ル、フェニルエチルトリシラノール、プロペニルトリシ
ラノール、シクロへキシルトリシラノール、メトキント
リシラノール、エトキシトリシラノールの１種又は２種
以上の混合物があげられる。又、メチル） ＩＪシラノ
ールの脱水縮合２量体、同３量体なども使用可能である
。上記各種化合物のうち、本発明では、特にメチルトリ
シラノールを用いるのが好ましい。The silicon compound used in the present invention may be any silicon compound as long as it has at least one silanol group in the molecule, but is preferably of the general formula (%): (wherein, R represents 1 to 1 carbon atoms. 12, preferably 1 to 6 alkyl, aralkyl, alkenyl, cycloalkyl, or alkoxy groups, two or more R's may be the same or different, and n is 0 to 3, preferably 1 to
It is an integer of 3. ) or dehydrated condensates thereof are preferably used. Specifically, these silicon compounds include methyltrisilanol, dimethyldisilanol, trimethylsilanol, ethyltrisilanol, diethyldisilanol, propyltrisilanol, octyltrisilanol, dodecyltrisilanol, benzyltrisilanol, and phenylethyltrisilanol. , propenyltrisilanol, cyclohexyltrisilanol, metquintrisilanol, and ethoxytrisilanol, or a mixture of two or more thereof. Furthermore, dehydrated condensed dimers and trimers of methyl) IJ silanol can also be used. Among the various compounds mentioned above, it is particularly preferable to use methyltrisilanol in the present invention.
上記シラノール基を有するケイ素化合物は、（１）対応
するハロゲン化プランを加水分解し、金属水酸化物と反
応させて得られるシリコネートを、カチオン交換樹脂あ
るいは各種酸にてｐＨを４〜５に調整して製造するか、
あるいは（ｉｉ） Ｎ応するアルコキンシランの加水
分解によって製造することができる。The above-mentioned silicon compound having a silanol group can be obtained by (1) hydrolyzing the corresponding halogenated plan, reacting it with a metal hydroxide, and adjusting the pH to 4 to 5 using a cation exchange resin or various acids; or manufacture it by
Alternatively, (ii) N can be produced by hydrolysis of a corresponding alkoxysilane.
これろのケイ素化合物は、そのまま又は水、エタノール
などの溶媒に溶解又は分散させた形態で使用可能である
。These silicon compounds can be used as they are or in a form dissolved or dispersed in a solvent such as water or ethanol.
本発明で用′７）るケイ素化合物は安全性上問題がない
っ次に該ケイ素化合物の安全性データを示す。The silicon compound used in the present invention has no safety problems, and the safety data of the silicon compound are shown below.
（フッｉ文ｒ′イ父→）
〔発明の効果〕
本発明で用いるケイ素化合物が有する細胞賦活作用の作
用機能は不明であるが、本発明によればすぐれた細胞賦
活剤が提供される。そこで、細胞を賦活化する結果とし
て、細胞の増斌作用を促進し、ヒアルロン酸合成等細胞
が有する種々の機能を促進させることができる。又、罰
偏部位の細胞の増殖をも促進させることができる。(Effects of the Invention) Although the cell activation function of the silicon compound used in the present invention is unknown, the present invention provides an excellent cell activation agent. Therefore, as a result of activating cells, it is possible to promote cell growth and promote various functions possessed by cells, such as hyaluronic acid synthesis. It can also promote the proliferation of cells in the affected area.
従って、本発明の細胞賦活剤は、例えば細胞培養用の添
加剤として、そのまま又はアミノ酸等の各種栄養源とと
もに使用することができる。尚、この際、本発明の細胞
賦活剤を１０−８〜１０−’Ｍの濃度で培地に用いるの
がよい。又、本発明の細 ・胞賦活剤は、釧傷治療用外
用剤として、例えば０．０１〜１０重量％含有し、かつ
殺菌・消毒薬などを含む形態として有効に利用できる。Therefore, the cell activator of the present invention can be used as it is or together with various nutritional sources such as amino acids, for example, as an additive for cell culture. In this case, it is preferable to use the cell activator of the present invention in the culture medium at a concentration of 10-8 to 10-'M. Further, the cell activator of the present invention can be effectively used as an external preparation for treating chisel wounds, for example, in a form containing 0.01 to 10% by weight and containing a bactericidal/disinfectant.
さらｊ二本発明の細胞賦活剤は、細胞の機能を活性化で
きる種々の用途、例えばリューマチ、強皮症、皮膚弛緩
症、荒れ肌、火傷、ひび、赤ぎれ、老人性乾皮症、痔戻
の予防と治療及び胃腸薬などに用いることができる。Furthermore, the cell activator of the present invention can be used for various purposes that can activate cell functions, such as rheumatism, scleroderma, cutis laxa, rough skin, burns, cracks, redness, senile xeroderma, and hemorrhoid recovery. It can be used for the prevention and treatment of cancer and as a gastrointestinal medicine.
次に本発明を実施例により説明するが、本発明はこれら
に限定されるものではない。Next, the present invention will be explained by examples, but the present invention is not limited thereto.
実施例１
メチルトリシラノールを次の方法により製造し、ヒトの
皮、百線准芽細胞を培養した時の細胞増殖能を測定した
。Example 1 Methyltrisilanol was produced by the following method, and its cell proliferation ability was measured when human skin and 100-centoblast cells were cultured.
メチルトリシラノールのＭ ａ方法
メチルトリクロルシランを加水分解して生じた沈殿を回
収、水洗、乾燥して、ポリマーを１等だ。M a method for methyltrisilanol The precipitate produced by hydrolyzing methyltrichlorosilane is collected, washed with water, and dried to obtain a polymer.
これを３倍モルの水酸化ナトリウム溶液に、溶解して、
トリソジウムメチルンリコ不−ト水溶液を調整した。こ
の水溶液を水で希釈し、陽イオン交換樹脂あるいは各種
酸にて、ｐＨを４〜５に調整し、メチルトリシラノール
水溶液を得た。Dissolve this in 3 times molar sodium hydroxide solution,
An aqueous solution of trisodium methylphosphonate was prepared. This aqueous solution was diluted with water, and the pH was adjusted to 4 to 5 using a cation exchange resin or various acids to obtain a methyltrisilanol aqueous solution.
細り包増殖能の測定
Ａ Ｔ ＣＣ（Ａｍｅｒｉｃａｎ Ｔｙｐｅ Ｃｕ１ｔ
ｕｒｅ Ｃｏ１ｅｃｔｉｏｎ）登録細胞の中からヒトの
真皮由来の正常線維芽細胞（細胞名ＣＲＬ−１５１３）
を選定して試験に供した。３５ｍｍシャーレに５万／ｄ
ｉｓｈずつ細胞を植え込み、１０％血清で２４時間培養
後、血清濃度を２％に落とし、各種１度のメチルトリシ
ラノールを添加して、培養し、６日後のＤＮＡ量を測定
した。Ｄ Ｎ Ａ量の測定法はジアミノ安息香酸による
螢光法を用いた。尚シャーレ；ま一検体当り４点ずつ調
製した。結果を表−１に示す。Measurement of thin follicle proliferation ability ATCC (American Type Cult)
Human dermis-derived normal fibroblasts (cell name CRL-1513) from registered cells
were selected and tested. 50,000/d for 35mm petri dish
After culturing in 10% serum for 24 hours, the serum concentration was lowered to 2%, 1 degree of each type of methyltrisilanol was added, cultured, and the amount of DNA was measured 6 days later. The amount of DNA was measured using a fluorescence method using diaminobenzoic acid. Four Petri dishes were prepared for each specimen. The results are shown in Table-1.
主 −１
±はＳ−Ｅを表わす
＊Ｉ コントロール
＊２ コントロールに対し５
％危険率で有意差あり
表−１から明らかなように、特にメチルトリシラノール
濃度１０−８〜１０４Ｍですぐれた細胞の増殖効果が得
られることがわかる。Main -1 ± represents S-E *I Control *2 Significant difference from control at 5% significance rate As is clear from Table 1, particularly at methyltrisilanol concentrations of 10-8 to 104M, excellent cell activity was observed. It can be seen that a proliferation effect can be obtained.
実施例２
ラット表皮細胞におけるヒアルロン酸合成能を次の手順
により測定した。Example 2 Hyaluronic acid synthesis ability in rat epidermal cells was measured by the following procedure.
まず、ウィスター（Ｗｉｓｔｅｒ ）系ラブドより表皮
細胞を採取し、２４ｗｅｌｌの７ヤーレに表皮細胞を２
、２ Ｘ Ｉ Ｏ５／ｄｉｓｈずつ及び！Ｊｔ、Ｃ−３
Ｔ ３細抱を６、６ Ｘ １０’ ／ｄｉｓｈずつ植
え込んで培養したところ、約６日後に密集した状ｐ （
ｃｏｎｆｌｕｅｎｔ）となった。植え込んで８日後に薬
物を添加して２４時間前処理した後、０．５ μｃｉ／
ｗｅｌｌ の１４Ｃ−グルコサミンを添加して、６時間
インキュベートした。First, epidermal cells were collected from Wistar rhabdo, and 2 epidermal cells were placed in 7 wells of 24 wells.
, 2 X I O5/dish each and! Jt, C-3
When 6.6 x 10'/dish of T3 clumps were planted and cultured, after about 6 days, a dense p (
It became confluent). Eight days after implantation, the drug was added and pretreated for 24 hours, followed by 0.5 μci/
14C-glucosamine was added to the well and incubated for 6 hours.
培養液を常法により分画してムコ多糖中のヒアルロン酸
合成に取り込まれたグルコサミンの放ＭｆｉＭを測定し
た。結果を表−２に示す。The culture solution was fractionated using a conventional method, and the released MfiM of glucosamine incorporated into the synthesis of hyaluronic acid in mucopolysaccharide was measured. The results are shown in Table-2.
表 −２
＊１ コントロール
＊２５％危険率でコントロールに対し、有意であること
を示す。Table 2 *1 Control * Indicates significance compared to control at 25% risk rate.
表−２に示したようにメチルトリシラノール濃度１０−
８〜１０−’Ｍで特にヒアルロン酸合成のすぐれた促進
効果が得られた。As shown in Table-2, methyltrisilanol concentration 10-
Particularly excellent promoting effects on hyaluronic acid synthesis were obtained at 8 to 10-'M.
実施例３
メチルトリシラノールの創傷治應促進効果を次のように
して測定した。Example 3 The wound healing promoting effect of methyltrisilanol was measured as follows.
ウィスター系ラットの雄（６週令）を４日間予備飼育し
、背中に直径１２．５ｍｍの欠損傷を作成した。傷口に
薬物を１００μｌ／匹ずつ２回７日ぬりつけ、傷口面積
を毎日測定した。尚−群は８匹である。結果を表−３に
示す。尚、薬物の内容は、コントロールは、生理食塩水
のみであり、メチルトリシラノールとしては生理食塩水
＋メチルトリシラノール０．５％を用いた。Male Wistar rats (6 weeks old) were preliminarily housed for 4 days, and a defective wound with a diameter of 12.5 mm was created on the back. The drug was applied to the wound twice for 7 days at 100 μl/mouse, and the wound area was measured every day. There were 8 animals in the group. The results are shown in Table-3. Regarding the drug contents, the control was only physiological saline, and the methyltrisilanol used was physiological saline + 0.5% methyltrisilanol.
表 −３ 実施例４ 次に本発明の細胞賦活剤を添加した各種組成物を示す。Table-3 Example 4 Next, various compositions to which the cell activator of the present invention is added are shown.
細胞用培地
イーグル（Ｅａｇｌｅ）の最小必須培地にメチルトリシ
ラノールを添加して調整したものであり、１０倍希釈し
て使用する。It is prepared by adding methyltrisilanol to Eagle's minimum essential medium for cells, and is used after being diluted 10 times.
Claims (3)
素化合物を含有することを特徴とする細胞賦活剤。(1) A cell activator characterized by containing a silicon compound having at least one silanol group in the molecule.
、Ｒは炭素数１〜１２のアルキル基、アラルキル基、ア
ルケニル基、シクロアルキル基、またはアルコキシ基で
あり、２以上のＲは互いに同一でも異なっても良く、ｎ
は０〜３の整数である。） で表わされる化合物又はこれらの脱水縮合体である特許
請求の範囲第（１）項記載の細胞賦活剤。(2) The silicon compound has the general formula (I): R_nSi(OH)_4_-_n...(I) (wherein R is an alkyl group having 1 to 12 carbon atoms, an aralkyl group, an alkenyl group, a cycloalkyl group) , or an alkoxy group, two or more R's may be the same or different, and n
is an integer from 0 to 3. ) or a dehydrated condensate thereof.
請求の範囲第（１）項記載の細胞賦活剤。(3) The cell activator according to claim (1), wherein the silicon compound is methyltrisilanol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15094786A JPS637779A (en) | 1986-06-27 | 1986-06-27 | Cell activator |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15094786A JPS637779A (en) | 1986-06-27 | 1986-06-27 | Cell activator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS637779A true JPS637779A (en) | 1988-01-13 |
Family
ID=15507895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP15094786A Pending JPS637779A (en) | 1986-06-27 | 1986-06-27 | Cell activator |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS637779A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2645863A1 (en) * | 1989-04-12 | 1990-10-19 | Voisin Philippe | Silicon compounds and process for the manufacture thereof |
-
1986
- 1986-06-27 JP JP15094786A patent/JPS637779A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2645863A1 (en) * | 1989-04-12 | 1990-10-19 | Voisin Philippe | Silicon compounds and process for the manufacture thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gospodarowicz et al. | Factors involved in the modulation of cell proliferation in vivo and in vitro: the role of fibroblast and epidermal growth factors in the proliferative response of mammalian cells | |
| Proper et al. | Mouse embryos contain polypeptide growth factor (s) capable of inducing a reversible neoplastic phenotype in nontransformed cells in culture | |
| Koyanagi et al. | Oversulfation of fucoidan enhances its anti-angiogenic and antitumor activities | |
| Younai et al. | Modulation of collagen synthesis by transforming growth factor-β in keloid and hypertrophic scar fibroblasts | |
| PRASAD | Morphological differentiation induced by prostaglandin in mouse neuroblastoma cells in culture | |
| Johnson-Wint | Regulation of stromal cell collagenase production in adult rabbit cornea: in vitro stimulation and inhibition by epithelial cell products. | |
| JPS59501905A (en) | animal tissue repair | |
| EA020779B1 (en) | METHOD OF TREATING CANCER USING A cMET AND AXL INHIBITOR AND AN ErbB INHIBITOR | |
| DE50102490D1 (en) | USE OF SUBSTITUTED IMIDAZO [1,2-A] PYRIDINE, PYRIMIDINE AND PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING MEDICINES FOR NOS INHIBITION | |
| DE69517054D1 (en) | USE OF INHIBITORS OF THE RECEPTOR OF BLOOD-PLASTIC-BASED GROWTH FACTORS FOR PRODUCING A MEDICINE FOR TREATING CANCER DISEASES | |
| JPH06509791A (en) | Methods and compositions for inhibiting angiogenesis | |
| JPS63239226A (en) | Therapeutical product based on organosilicon derivative | |
| Ryan | Endothelial cells | |
| KR860000900B1 (en) | Producing method of human luteinizing hormone | |
| Yamamoto et al. | In vitro evidence from tissue cultures to prove existence of rabbit and human renotropic growth factor | |
| JPS637779A (en) | Cell activator | |
| KR100385293B1 (en) | Method for cell adhesion and wound healing with domains of βig-h3 | |
| Okabe et al. | Growth factor (s) produced by a human leukemic cell line growing in a protein-free chemically defined medium | |
| JP7074995B2 (en) | Fibroblast growth promoter and elastin production promoter in fibroblasts | |
| JP2017136014A (en) | Method for producing m2-like macrophage composition, and m2-like macrophage composition raw material | |
| Bradley et al. | Factors determining colony forming efficiency in agar suspension cultures. | |
| JPS624117B2 (en) | ||
| HRP20140247T1 (en) | Anti-cancer vaccine | |
| Wientroub et al. | Changes in tissue concentration of prostaglandins during endochondral bone differentiation | |
| JPH03505732A (en) | movement stimulator |